Pharmaceutical cartel probe by Chinese regulator yields new individual penalty
By MLex Staff ( May 6, 2025, 08:57 GMT | Insight) -- A second individual has been penalized in China following a cartel investigation into a key drug raw material, this time involving a probe by the Tianjin antitrust regulator. Notably, in addition to a total penalty amounting to 195.3 million yuan ($27.1 million) on Xianju Pharmaceutical, the company’s president, Zhang Yusong, was fined 600,000 yuan for his personal liability in the company’s compliance failure. The penalty was imposed just a few weeks after a separate decision by the Shanghai market regulator into another pharmaceutical company's executive, exposing heightened compliance risks to individuals responsible for misconduct.
A second individual has been penalized in China following a cartel investigation into a key drug raw material, this time involving a probe by the Tianjin antitrust regulator. Earlier today, Zhejiang-based and Shenzhen-listed Xianju Pharmaceutical disclosed in its stock filing that it received an antitrust penalty decision from the market regulator on April 30, for reaching and implementing monopolistic agreements in the market for the active pharmaceutical ingredient, or API, dexamethasone sodium phosphate. Notably, in addition to a total penalty amounting to 195.3 million yuan ($27.1 million) on Xianju Pharmaceutical, the company’s president, Zhang Yusong, was fined 600,000 yuan for his personal liability in the company’s compliance failure. The penalty was imposed just a few weeks after a separate decision by the Shanghai market regulator into another pharmaceutical company's executive, exposing heightened compliance risks to individuals responsible for misconduct....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
Curated case files bringing together news, analysis and source documents in a single timeline